Literature DB >> 1767633

The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time.

R Schröder1, K Bien, R Kott, I Meyers, R Vössing.   

Abstract

The monoclonal antibody (mAb) Ki-67 is a marker for the growth fraction (GF) of tumor cells. The exact relationship between the Ki-67 labeling index (LI) and the conventional diagnostic criterion of the proliferative activity of brain tumors, the mitotic index (MI), is unknown except for some general references. On serial frozen sections Ki-67 LI and MI were determined in nearly identical areas of 32 glioblastomas, 20 grade III astrocytomas, 21 grade II astrocytomas and 20 selected cases of meningioma. The data not only clearly showed different median values of LI and MI for the various malignancy grades, but also similar regression coefficients for each glioma type. A non-linear relationship between the two indices was found for all glioma cases with high significance and high correlation coefficient; (LI) = 5.6 (MI)0.59. This results from differing intermitotic cycle times, the variability of which can be estimated from the data given.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1767633     DOI: 10.1007/bf00296550

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  33 in total

1.  [Cell kinetics of oligodendroglioma and oligo-astrocytoma--Ki-67 PaP study].

Authors:  T Shibata; P C Burger; P Kleihues
Journal:  No To Shinkei       Date:  1988-08

2.  The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology.

Authors:  P C Burger; T Shibata; P Kleihues
Journal:  Am J Surg Pathol       Date:  1986-09       Impact factor: 6.394

3.  Cell kinetics of human gliomas.

Authors:  T Hoshino; M Barker; C B Wilson; E B Boldrey; D Fewer
Journal:  J Neurosurg       Date:  1972-07       Impact factor: 5.115

4.  The technique of labelled mitoses: analysis by automatic curve-fitting.

Authors:  G G Steel; S Hanes
Journal:  Cell Tissue Kinet       Date:  1971-01

5.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

6.  The monoclonal antibody Ki-67 as a marker for proliferating cells in stereotactic biopsies of brain tumours.

Authors:  C B Ostertag; B Volk; T Shibata; P Burger; P Kleihues
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

7.  Volume corrected mitotic index (M/V-INDEX). The standard of mitotic activity in neoplasms.

Authors:  H Haapasalo; E Pesonen; Y Collan
Journal:  Pathol Res Pract       Date:  1989-11       Impact factor: 3.250

8.  The proliferation rate of intracranial tumors as defined by the monoclonal antibody KI 67. Application of the method to paraffin embedded specimens.

Authors:  D K Böker; H J Stark
Journal:  Neurosurg Rev       Date:  1988       Impact factor: 3.042

9.  The use of the monoclonal antibody Ki-67 in determination of the growth fraction in pediatric brain tumors.

Authors:  T Shibata; P C Burger
Journal:  Childs Nerv Syst       Date:  1987       Impact factor: 1.475

10.  Immunohistochemical demonstration of DNA polymerase alpha in human brain-tumor cells.

Authors:  K Kunishio; N Mishima; T Matsuhisa; K Tsuno; N Matsumi; T Satoh; K Matsumoto; T Furuta; A Nishimoto; T Shiraishi
Journal:  J Neurosurg       Date:  1990-02       Impact factor: 5.115

View more
  18 in total

1.  Ki-67 immunostaining as a tool in the diagnosis of central cartilage lesions.

Authors:  L J Weinstein; E F McCarthy
Journal:  Iowa Orthop J       Date:  1996

2.  Triple approach for diagnosis and grading of meningiomas: histology, morphometry of Ki-67/Feulgen stainings, and cytogenetics.

Authors:  H Kolles; I Niedermayer; C Schmitt; W Henn; R Feld; W I Steudel; K D Zang; W Feiden
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

Review 3.  The role of surgery in low grade gliomas.

Authors:  J Bampoe; M Bernstein
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

4.  Ki-67 labeling is correlated with the time to recurrence in primary glioblastomas.

Authors:  Roland Schröder; Klaus D Feisel; Ralf-Ingo Ernestus
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

5.  Proliferating cell nuclear antigen immunoreactivity in human central nervous system neoplasms.

Authors:  E Karamitopoulou; E Perentes; M Melachrinou; T Maraziotis
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

6.  Regional differences in bromodeoxyuridine uptake, expression of Ki-67 protein, and nucleolar organizer region counts in glioblastoma multiforme.

Authors:  K Onda; R L Davis; C B Wilson; T Hoshino
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

7.  Potential doubling time and tumour doubling time in meningiomas and neurinomas.

Authors:  S Nakasu; Y Nakasu; M Nakajima; M Yokoyama; M Matsuda; J Handa
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

8.  Combined Ki-67 and Feulgen stain for morphometric determination of the Ki-67 labelling index.

Authors:  H Kolles; W Förderer; R Bock; W Feiden
Journal:  Histochemistry       Date:  1993-10

9.  The growth potential of ependymomas with varying grades of malignancy measured by the Ki-67 labelling index and mitotic index.

Authors:  R Schröder; C Ploner; R I Ernestus
Journal:  Neurosurg Rev       Date:  1993       Impact factor: 3.042

10.  Proliferation rate of intracranial meningiomas as defined by the monoclonal antibody MIB-1: correlation with peritumoural oedema and other clinicoradiological and histological characteristics.

Authors:  Paulo Henrique Aguiar; Ana Maria Tsanaclis; Oswaldo Inácio Tella; José Pindaro Plese
Journal:  Neurosurg Rev       Date:  2003-04-08       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.